NCT01331824View on ClinicalTrials.gov

Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2015

Conditions
Bladder Cancer
Interventions
DRUG

Amrubicin

Patients will receive 35 mg/m2/day of amrubicin intravenously for 3 consecutive days as the initial dose starting on Day 1 of a 21-day cycle for up to 6 cycles

Trial Locations (3)

10029

Icahn School of Medicine at Mount Sinai, New York

46202

Indiana University Simon Cancer Center, Indianapolis

85234

Banner MD Anderson Cancer Center, Gilbert

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Matthew Galsky

OTHER